Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Plus Chemotherapy in ALK+ NSCLC Post-Lorlatinib Progression
NCT05948462Phase 2Withdrawn
- Sponsor
- SCRI Development Innovations
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by SCRI Development Innovations. Planned start Nov 2023; status: withdrawn.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05948462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05948462.